Lenzing Aktiengesellschaft

LSE:0NCV Stock Report

Market Cap: €1.1b

Lenzing Valuation

Is 0NCV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0NCV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0NCV (€27.5) is trading below our estimate of fair value (€84.57)

Significantly Below Fair Value: 0NCV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0NCV?

Key metric: As 0NCV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0NCV. This is calculated by dividing 0NCV's market cap by their current revenue.
What is 0NCV's PS Ratio?
PS Ratio0.4x
Sales€2.61b
Market Cap€1.07b

Price to Sales Ratio vs Peers

How does 0NCV's PS Ratio compare to its peers?

The above table shows the PS ratio for 0NCV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.7x
ESNT Essentra
1.2x1.8%UK£374.1m
ZTF Zotefoams
1.1x6.6%UK£149.2m
VCT Victrex
3.2x4.5%UK£918.3m
ELM Elementis
1.4x3.4%UK£830.0m
0NCV Lenzing
0.4x2.5%€1.1b

Price-To-Sales vs Peers: 0NCV is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does 0NCV's PS Ratio compare vs other companies in the GB Chemicals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
JMAT Johnson Matthey
0.2x-32.7%US$2.81b
SYNT Synthomer
0.1x5.0%US$317.84m
CAR Carclo
0.1x9.7%US$23.84m
HEIQ HeiQ
0.2xn/aUS$9.61m
0NCV 0.4xIndustry Avg. 1.2xNo. of Companies7PS01.22.43.64.86+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0NCV is good value based on its Price-To-Sales Ratio (0.4x) compared to the UK Chemicals industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is 0NCV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0NCV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: 0NCV is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0NCV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€27.50
€33.14
+20.5%
3.6%€35.00€32.00n/a5
Dec ’25€29.28
€33.14
+13.2%
3.6%€35.00€32.00n/a5
Nov ’25€31.38
€34.04
+8.5%
2.6%€35.00€32.70n/a5
Oct ’25€35.13
€34.04
-3.1%
2.6%€35.00€32.70n/a5
Sep ’25€30.85
€34.04
+10.3%
2.6%€35.00€32.70n/a5
Aug ’25€32.25
€34.26
+6.2%
2.7%€35.00€32.80n/a5
Jul ’25€33.27
€34.26
+3.0%
2.7%€35.00€32.80n/a5
Jun ’25€34.50
€34.26
-0.7%
2.7%€35.00€32.80n/a5
May ’25€30.60
€31.26
+2.2%
11.3%€35.00€25.00n/a5
Apr ’25€31.84
€32.26
+1.3%
11.6%€35.00€25.00n/a5
Mar ’25€29.70
€36.66
+23.4%
12.0%€45.00€32.80n/a5
Feb ’25€30.60
€40.80
+33.3%
13.2%€45.50€33.50n/a5
Jan ’25€35.55
€43.60
+22.6%
5.5%€45.50€39.00n/a5
Dec ’24€34.80
€44.60
+28.1%
7.9%€50.00€39.00€29.285
Nov ’24€36.60
€46.33
+26.6%
8.5%€51.00€39.00€31.386
Oct ’24€38.85
€50.83
+30.8%
20.1%€72.00€39.00€35.136
Sep ’24€43.55
€50.83
+16.7%
20.1%€72.00€39.00€30.856
Aug ’24€46.13
€62.04
+34.5%
20.3%€74.20€39.00€32.255
Jul ’24€44.84
€62.04
+38.4%
20.3%€74.20€39.00€33.275
Jun ’24€54.46
€62.04
+13.9%
20.3%€74.20€39.00€34.505
May ’24€58.82
€65.04
+10.6%
20.7%€75.00€39.00€30.605
Apr ’24€69.40
€65.04
-6.3%
20.7%€75.00€39.00€31.845
Mar ’24€70.90
€74.64
+5.3%
41.2%€130.00€39.00€29.705
Feb ’24€66.83
€73.90
+10.6%
41.6%€130.00€39.00€30.605
Jan ’24€55.15
€73.90
+34.0%
41.6%€130.00€39.00€35.555
Dec ’23€66.00
€73.90
+12.0%
41.6%€130.00€39.00€34.805

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 02:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lenzing Aktiengesellschaft is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard SchwarzBaader Helvea Equity Research
Sebastian BrayBerenberg
Ingo-Martin SchachelBNP Paribas Exane